B. Osterud and S. I. Rapaport, Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation., Proceedings of the National Academy of Sciences, vol.74, issue.12, pp.5260-5264, 1977.
DOI : 10.1073/pnas.74.12.5260

F. S. Hagen, C. L. Gray, and P. O. Hara, Characterization of a cDNA coding for human factor VII., Proceedings of the National Academy of Sciences, vol.83, issue.8, pp.2412-2416, 1986.
DOI : 10.1073/pnas.83.8.2412

A. C. P-i-k-e, A. M. B-r-z-o-z-o-w-s-k-i, S. M. R-o-b-e-r-t-s, O. H. Olsen, and E. Persson, Structure of human factor VIIa and its implications for the triggering of blood coagulation, Proceedings of the National Academy of Sciences of the United States of America, vol.96, issue.16, pp.8925-8930, 1999.

F. Hagen and M. Murray, Expression of factor VII activity in mammalian cells, pp.784-950, 1988.

U. Hedner and C. A. Lee, First 20???years with recombinant FVIIa (NovoSeven), Haemophilia, vol.13, issue.Suppl. 1, pp.172-182, 2011.
DOI : 10.1111/j.1365-2516.2010.02352.x

R. B. Weiskopf, Recombinant-activated coagulation factor VIIa (NovoSeven??): current development, Vox Sanguinis, vol.3, issue.Suppl 1, pp.281-288, 2007.
DOI : 10.1111/j.1423-0410.2006.00888.x

A. Mayo, M. Misgav, and Y. Kluger, Recombinant activated factor VII (NovoSeventm): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding, Vox Sanguinis, vol.9, issue.1, pp.34-40, 2004.
DOI : 10.1177/00912700122010780

M. Levi, M. Peters, and H. R. Büller, Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review, Critical Care Medicine, vol.33, issue.4, pp.883-890, 2005.
DOI : 10.1097/01.CCM.0000159087.85970.38

M. Levi, J. H. Levy, H. F. Andersen, and D. Truloff, Safety of Recombinant Activated Factor VII in Randomized Clinical Trials, New England Journal of Medicine, vol.363, issue.19, pp.1791-1800, 2010.
DOI : 10.1056/NEJMoa1006221

N. Masroori, R. Halabian, and M. Mohammadipour, High-level expression of functional recombinant human coagulation factor VII in insect cells, Biotechnology Letters, vol.254, issue.6, pp.803-809, 2010.
DOI : 10.1007/s10529-010-0227-7

I. , A. M. Roushandeh, and A. J. Najafabadi, E s m a e i l i Establishment of a cell line expressing recombinant factor VII and its subsequent conversion to active form FVIIa through hepsin by genetic engineering method, Vox Sanguinis, vol.96, issue.4, pp.309-315, 2009.

R. Sodoyer, F. Hesse, and R. Wagner, Expression systems for the production of recombinant pharmaceuticals Developments and improvements in the manufacturing of human therapeutics with mammalian cell cultures, BioDrugs Trends in Biotechnology, vol.1813, issue.18 4, pp.51-62, 2000.

R. Breitling, S. Klingner, and N. Callewaert, Non-pathogenic trypanosomatid protozoa as a platform for protein research and production, Protein Expression and Purification, vol.25, issue.2, pp.209-218, 2002.
DOI : 10.1016/S1046-5928(02)00001-3

C. Fritsche, M. Sitz, N. Weiland, R. Breitling, and H. D. , Characterization of the growth behavior ofLeishmania tarentolae ??? a new expression system for recombinant proteins, Journal of Basic Microbiology, vol.36, issue.5, pp.384-393, 2007.
DOI : 10.1002/jobm.200710111

C. Fritsche, M. Sitz, M. Wolf, and H. D. , Development of a defined medium for heterologous expression in Leishmania tarentolae, Journal of Basic Microbiology, vol.86, pp.488-495, 2008.

B. Kazemi, G. Tahvildar, S. R. Feshareki, and E. E. Javadian, Isolation a lizard Leishmania promastigote from natural host in Iran, Journal of Biological Sciences, vol.4, issue.5, pp.620-623, 2004.

S. Koizume, M. S. Jin, and E. Miyagi, Activation of Cancer Cell Migration and Invasion by Ectopic Synthesis of Coagulation Factor VII, Cancer Research, vol.66, issue.19, pp.9453-9460, 2006.
DOI : 10.1158/0008-5472.CAN-06-1803

W. Gaastra and K. Hansen, Ligation of DNA with t 4 DNA ligase, Methods in Molecular Biology, vol.2, pp.225-230, 1985.

D. Hanahan, Studies on transformation of Escherichia coli with plasmids, Journal of Molecular Biology, vol.166, issue.4, pp.557-580, 1983.
DOI : 10.1016/S0022-2836(83)80284-8

K. A. Robinson and S. M. Beverley, Improvements in transfection efficiency and tests of RNA interference (RNAi) approaches in the protozoan parasite Leishmania, Molecular and Biochemical Parasitology, vol.128, issue.2, pp.217-228, 2003.
DOI : 10.1016/S0166-6851(03)00079-3

M. Soleimani, F. Mahboudi, and N. Davoudi, Expression of human tissue plasminogen activator in the trypanosomatid protozoan Leishmania tarentolae, Biotechnology and Applied Biochemistry, vol.48, issue.1, pp.55-61, 2007.

H. P. Phan, M. Sugino, and T. Niimi, The production of recombinant human laminin-332 in a Leishmania tarentolae expression system, Protein Expression and Purification, vol.68, issue.1, pp.79-84, 2009.
DOI : 10.1016/j.pep.2009.07.005

R. Toso, M. Pinotti, K. A. High, E. S. Pollak, and F. Bernardi, A frequent human coagulation Factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates, Biochemical Journal, vol.363, issue.2, pp.411-416, 2002.
DOI : 10.1042/bj3630411

E. Handman, Cell Biology of Leishmania, Advances in Parasitology, vol.44, pp.1-39, 1999.
DOI : 10.1016/S0065-308X(08)60229-8

S. M. Ruiz, S. Sridhara, M. A. Blajchman, and B. J. Clarke, Expression and Purification of Recombinant Rabbit Factor VII, Thrombosis Research, vol.98, issue.2, pp.203-211, 2000.
DOI : 10.1016/S0049-3848(99)00227-3

N. Wajih, J. Owen, and R. Wallin, Enhanced functional recombinant factor VII production by HEK 293 cells stably transfected with VKORC1 where the gamma-carboxylase inhibitor calumenin is stably suppressed by shRNA transfection, Thrombosis Research, vol.122, issue.3, pp.405-410, 2008.
DOI : 10.1016/j.thromres.2007.11.002

A. J. Parodi, -Glycosylation in trypanosomatid protozoa, Glycobiology, vol.3, issue.3, pp.193-199, 1993.
DOI : 10.1093/glycob/3.3.193

URL : https://hal.archives-ouvertes.fr/jpa-00210117

G. Bolt, C. Kristensen, and T. D. Steenstrup, Posttranslational N-glycosylation takes place during the normal processing of human coagulation factor VII, Glycobiology, vol.15, issue.5, pp.541-547, 2005.
DOI : 10.1093/glycob/cwi032

P. Margaritis, V. R. Arruda, M. Aljamali, R. M. Camire, A. Schlachterman et al., Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII, Journal of Clinical Investigation, vol.113, issue.7, pp.1025-1031, 2004.
DOI : 10.1172/JCI20106